Efavirenz reclassified as FDA pregnancy category D.
Mofenson
Lynne M
LM
Pediatric, Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA.
D000014:Abnormalities, Drug-Induced; D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D005260:Female; D005333:Fetus / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010078:Oxazines / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz